National Center for Injury Prevention and Control, Initial Review Group, (NCIPC, IRG), 66901 [E8-26801]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 219 / Wednesday, November 12, 2008 / Notices
promotion programs; administering a
national occupational safety and health
program; controlling the introduction and
spread of infectious diseases; and providing
consultation and assistance to other nations
and international agencies to assist in
improving their disease prevention and
control, environmental health, and health
promotion activities. CDC carries out these
functions through a number of Coordinating
Centers/Offices and National Centers and
Institutes with expertise and responsibilities
in specific areas.
Matters to be Discussed: The agenda will
include discussions on program activities,
including scientific programs, that will assist
in consolidating and refining NCHM vision,
mission, goals, organizational structure and
expanding and implementing its science for
the National Center for Health Marketing;
and discussions related to the National
Center’s role in preparedness, response and
recovery with regards to an outbreak of
pandemic influenza
Agenda items are tentative and subject to
change.
Contact Person for More Information:
Dionne R. Mason, Committee Management
Specialist, NCHM, 1600 Clifton Road, Mail
Stop E–21, Atlanta, Georgia 30333,
Telephone: (404) 498–2314, Fax (404) 498–
2221. The deadline for notification of
attendance is November 20, 2008.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: November 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention (CDC).
[FR Doc. E8–26803 Filed 11–10–08; 8:45 am]
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct specific
injury research that focuses on prevention
and control.
Matters to be Discussed: The meeting will
include the reporting and voting of the peer
reviews conducted in response to Fiscal Year
2008 Requests for Applications related to the
following individual research
announcements: (1) RFA–CD–08–001,
‘‘Elimination of Health Disparities Through
Translation Research (R18)’’ and (2) RFA–
CE–09–001, ‘‘Grants for the Injury Control
Research Centers’’. Agenda items are subject
to change as priorities dictate.
Contact Person for More Information: Rick
Waxweiler, PhD, Director, Extramural
Research Program Office, NCIPC and
Executive Secretary, NCIPC IRG, CDC, 4770
Buford Highway, NE., Mail Stop F–62,
Atlanta, Georgia 30341, Telephone: (770)
488–4850.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: November 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–26801 Filed 11–10–08; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Centers for Disease Control and
Prevention (CDC)
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Current Good
Manufacturing Practices and Related
Regulations for Blood and Blood
Components; and Requirements for
Donor Testing, Donor Notification, and
‘‘Lookback’’
[Docket No. FDA–2008–N–0345]
National Center for Injury Prevention
and Control, Initial Review Group,
(NCIPC, IRG)
mstockstill on PROD1PC66 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), CDC announces the
following meeting for the
aforementioned committee:
Times and Date: 1 p.m.–2:30 p.m.,
December 8, 2008 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5,
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Section 10(d) of Public Law
92–463.
VerDate Aug<31>2005
18:30 Nov 10, 2008
Jkt 217001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
66901
Fax written comments on the
collection of information by December
12, 2008.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0116. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
DATES:
Current Good Manufacturing Practices
and Related Regulations for Blood and
Blood Components; and Requirements
for Donor Testing, Donor Notification,
and ‘‘Lookback’’ (OMB Control Number
0910–0116—Extension)
All blood and blood components
introduced or delivered for introduction
into interstate commerce are subject to
section 351(a) of the Public Health
Service Act (PHS Act) (42 U.S.C. 262).
Section 351(a) requires that
manufacturers of biological products,
which include blood and blood
components intended for further
manufacture into injectable products,
have a license, issued upon a
demonstration that the product is safe,
pure and potent and that the
manufacturing establishment meets all
applicable standards, including those
prescribed in the FDA regulations
designed to ensure the continued safety,
purity, and potency of the product. In
addition, under section 361 of the PHS
Act (42 U.S.C. 264), by delegation from
the Secretary of Health and Human
Services, FDA may make and enforce
regulations necessary to prevent the
introduction, transmission, or spread of
communicable diseases from foreign
countries into the States or possessions,
or from one State or possession into any
other State or possession.
Section 351(j) of the PHS Act states
that the Federal Food, Drug, and
Cosmetic (FD&C) Act also applies to
biological products. Blood and blood
components for transfusion or for
further manufacture into injectable
products are drugs, as that term is
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 73, Number 219 (Wednesday, November 12, 2008)]
[Notices]
[Page 66901]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26801]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention (CDC)
National Center for Injury Prevention and Control, Initial Review
Group, (NCIPC, IRG)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), CDC announces the following meeting for
the aforementioned committee:
Times and Date: 1 p.m.-2:30 p.m., December 8, 2008 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5,
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Section 10(d) of Public Law
92-463.
Purpose: This group is charged with providing advice and
guidance to the Secretary, Department of Health and Human Services,
and the Director, CDC, concerning the scientific and technical merit
of grant and cooperative agreement applications received from
academic institutions and other public and private profit and
nonprofit organizations, including State and local government
agencies, to conduct specific injury research that focuses on
prevention and control.
Matters to be Discussed: The meeting will include the reporting
and voting of the peer reviews conducted in response to Fiscal Year
2008 Requests for Applications related to the following individual
research announcements: (1) RFA-CD-08-001, ``Elimination of Health
Disparities Through Translation Research (R18)'' and (2) RFA-CE-09-
001, ``Grants for the Injury Control Research Centers''. Agenda
items are subject to change as priorities dictate.
Contact Person for More Information: Rick Waxweiler, PhD,
Director, Extramural Research Program Office, NCIPC and Executive
Secretary, NCIPC IRG, CDC, 4770 Buford Highway, NE., Mail Stop F-62,
Atlanta, Georgia 30341, Telephone: (770) 488-4850.
The Director, Management Analysis and Services Office has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: November 4, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E8-26801 Filed 11-10-08; 8:45 am]
BILLING CODE 4163-18-P
